about
The systemic theory of living systems and relevance to CAM: the theory (Part III).Role of cerebral cortex in the neuropathology of Huntington's diseasePGC-1α, mitochondrial dysfunction, and Huntington's diseaseMitochondrial dysfunction in neurodegenerative diseasesInhibition of mitochondrial protein import by mutant huntingtinPGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neuronsImpaired brain creatine kinase activity in Huntington's disease.PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.Laquinimod treatment in the R6/2 mouse model.Reduced creatine kinase as a central and peripheral biomarker in Huntington's diseaseThe neurodegenerative mitochondriopathies.Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.Mitochondrial loss, dysfunction and altered dynamics in Huntington's diseaseTetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycleMeclizine is neuroprotective in models of Huntington's disease.Dysfunctional mitochondrial respiration in the striatum of the Huntington's disease transgenic R6/2 mouse model.ROC-supervised principal component analysis in connection with the diagnosis of diseasesMitochondrial Medicine and the Neurodegenerative Mitochondriopathies.Application of clustering analyses to the diagnosis of Huntington disease in mice and other diseases with well-defined group boundariesTruncated peroxisome proliferator-activated receptor-γ coactivator 1α splice variant is severely altered in Huntington's diseaseMitochondrial medicine for aging and neurodegenerative diseasesSelective defect of in vivo glycolysis in early Huntington's disease striatumPharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's diseaseMitochondria as a therapeutic target for aging and neurodegenerative diseases.Mitochondrial DNA, base excision repair and neurodegeneration.Normal platelet mitochondrial complex I activity in Huntington's disease.Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.The genetics of neurodegenerative diseases.Mitochondria-targeted peptide antioxidants: novel neuroprotective agentsAbnormal Weight and Body Mass Index in Children with Juvenile Huntington's Disease.Protein expression in the striatum and cortex regions of the brain for a mouse model of Huntington's disease.Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria.Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications.Impaired regulation of brain mitochondria by extramitochondrial Ca2+ in transgenic Huntington disease ratsAltered lipid metabolism in Drosophila model of Huntington's disease.Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.
P2860
Q24816758-507DF909-5315-4E39-9CD2-4E04CA2028E5Q26829211-E8992E6A-CA00-4103-8E47-4E902A246847Q27001671-758DE04F-F667-4696-8EC3-3FBCB80FB683Q28387647-3C4F40DD-4190-4B4A-8EB0-46030AE4E769Q28394803-EFAFB917-8A6A-4F56-853C-3B09BD6421C0Q28583359-56FC3E66-9640-43EC-8D26-88FB6C111B4DQ30468147-970F42E6-EDF7-404C-9461-0291C0FFA2EFQ30583566-91E26175-63D5-43E2-BC4D-F629EE05F3A1Q33291754-0A2AC513-BA35-4C6C-9797-D16552BFF4A1Q33457162-CD39E66D-47C5-446F-B36C-F510D0A6D9D9Q33890346-BD1E6291-9D90-4834-B4A6-04DF22F643C4Q33945688-C9249840-524F-444C-81AB-F6BEA900A1D3Q33957065-288207CA-DCB1-4778-B3AA-FA912DBDCC96Q34153434-C7DA7C04-09E1-45E9-AC50-4224F0221280Q34163054-5D4156BE-0B36-4C2E-8D71-37B69ED0249DQ34184185-C52C82FB-F2F9-4807-BB56-72EA3BFFE0F6Q34284039-97F420BB-03B0-443F-9434-84EB8997E331Q34352145-A215B1CC-4398-490E-B305-4E0599F2A810Q34424265-76064C86-61DF-44CC-80B9-C6B8707CF1DCQ34659907-30A17FBA-1DF0-44A8-A080-ED1FAF4DACACQ34667446-C5AC46BE-EBD1-4409-8C66-4334E7BB24C9Q35140660-8ED885E4-7486-4A96-9CF7-12257AC15F1BQ35195079-46DC2E78-F85C-4724-8041-0C510F0739E9Q35268092-AA2BF6C5-1334-4B45-A392-204BB571DF64Q35606693-C894782C-F004-47B7-8CE9-DD7ED326BF1FQ35634060-748BE55D-F868-4FD6-BD2F-C06F11F43F0AQ35750228-F178AA80-2DEA-49CE-85D6-4EEF7C775361Q35807409-FB237B01-468C-4285-99B1-BBC13881C040Q36223869-1FBF17BE-0A3F-48DE-91D9-AC20554594D9Q36274461-F07C6234-5A2A-44FF-BB19-D23549C3B55BQ36379946-F75C7655-A62D-4847-A679-A29DEF34A8EAQ36521941-56479275-94EF-4DBB-A9AE-7F5AA8EF93F8Q36616338-74FE2116-53AA-4D57-B908-774DC30E939EQ36950717-38E6FAC8-4EEF-4ABF-A530-3673847794D0Q36960406-9DA35B48-1E43-4600-92DE-D63CA81DA278Q37001587-3F1AAAB0-9069-41D8-AC3E-1A294568C033Q37003956-9AE38243-FC99-4950-AAD4-9B5A7B4B00E4Q37142702-FBA8E8A0-0646-48E3-9E07-758F7460DC64Q37163313-6A30E219-3AF0-41BD-8171-E88FDF0C3B5AQ37211755-0AB32023-0FE3-4A7A-886F-9677BB4A6232
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The energetics of Huntington's disease.
@ast
The energetics of Huntington's disease.
@en
The energetics of Huntington's disease.
@nl
type
label
The energetics of Huntington's disease.
@ast
The energetics of Huntington's disease.
@en
The energetics of Huntington's disease.
@nl
prefLabel
The energetics of Huntington's disease.
@ast
The energetics of Huntington's disease.
@en
The energetics of Huntington's disease.
@nl
P1476
The energetics of Huntington's disease.
@en
P2093
M Flint Beal
Susan E Browne
P304
P356
10.1023/B:NERE.0000014824.04728.DD
P577
2004-03-01T00:00:00Z
P6179
1008565354